PPT-A ssessment of D ual antiplatelet therapy versus

R ivaroxaban I n atrial F ibrillation patients T reated with left atrial appendage closure ADRIFT investigators DOI public at wwwactioncoeurorg Healing 30 days to 3 months Kar et al JACC Intv 201478019. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Tx. : . Real-World Practice. In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx. 1. Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . P . Stather. , N . Dattani. , D . Sidloff. On Behalf of VERN. Background. Abdominal Aortic Aneurysm (AAA) increases cardiovascular (CV) risk. NAAASP recommends BP and lipid control. ESVS recommends antiplatelet. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC A ssessment of D ual antiplatelet therapy versus R ivaroxaban I n atrial F ibrillation patients T reated with left atrial appendage closure ADRIFT investigators DOI public at www.action-coeur.org Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.